article thumbnail

Pharmapack Europe 2025: Eco barrier packaging to launch

European Pharmaceutical Review

LOG Pharma Primary Packaging is set to present its new barrier eco line at Pharmapack Europe 2025. LOGs barrier packaging solutions are designed to prolong shelf life and protect innovative and generic drugs from the exposure to moisture and/or oxygen, the company explained on its website.

Packaging 105
article thumbnail

Anti-Counterfeit Packaging Market Estimated to Reach Nearly $436 Million by 2030

Pharmaceutical Commerce

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmapack Europe to launch two new zones in 2024

European Pharmaceutical Review

In 2024, Pharmapack Europe, the two-day exhibition and conference for pharma’s drug delivery and packaging industry will introduce two brand new zones to the flagship event. Bio packaging zone . Pharmapack’s bio packaging zone builds on its long history of being at the forefront of innovations in biological drug delivery.

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. These chemicals are everywhere and have been used in many ways over the decades, bringing a range of benefits from water- and stain-resistant coatings and firefighting foams to nail polish and food packaging.

article thumbnail

Pharma contract manufacturing market to grow to $130bn by 2026

European Pharmaceutical Review

According to the report, the packaging segment of the market will be worth $15.6 billion by 2026, as contract manufacturing organisations increasingly adopt newer and efficient ways to package products, increasing demand for new machinery. For instance, efforts are underway to automate packaging of personalised cell and gene therapies.

article thumbnail

Lilly and EVA Pharma to aid affordable insulin access in Africa

European Pharmaceutical Review

Lilly’s 30×30 initiative aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030. Mikkelsen added that “the hope is to have insulin and diabetes devices as part of Essential Benefit Packages in low- and middle-income countries towards achieving Universal Health Coverage.”

article thumbnail

Takeda to invest €300 million in plasma-derived therapy production

European Pharmaceutical Review

The plant is specialised in the purification and filling of plasma-derived therapies, with packaging capabilities for a variety of plasma treatments. We aim to become a net-zero carbon emissions operation by 2030 and have a clear focus on further digitalisation.